Medina Boualit
Valenciennes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: March 05, 2024
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease.
Journal: Journal of Crohn's & colitis
Published: November 27, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Journal: Alimentary pharmacology & therapeutics
Published: May 22, 2020
Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study.
Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: May 08, 2020
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Journal: Digestive diseases and sciences
Published: April 25, 2019
Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.
Journal: Journal of Crohn's & colitis
Published: February 23, 2019
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.
Journal: Inflammatory bowel diseases
Published: August 25, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents.
Journal: The American journal of gastroenterology
Published: December 02, 2016
Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 28, 2016
Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score.
Journal: Digestive diseases and sciences
Published: March 16, 2016
Last Updated: 09/26/2026